Table 3.
Candidate vaccines for COVID-19 (as of June, 2021)
| Vaccine platform description | Candidate vaccines in clinical phase (No.) | Candidate vaccines in pre-clinical phase (No.) |
|---|---|---|
| Protein subunit | 32 | 72 |
| Viral vector (non-replicating) | 16 | 21 |
| Inactivated virus | 16 | 9 |
| RNA based vaccine | 16 | 24 |
| DNA based vaccine | 10 | 16 |
| Virus like particle | 5 | 18 |
| Viral vector (replicating) | 2 | 19 |
| Viral vector (replicating) + antigen presenting cell | 2 | 0 |
| Live attenuated virus | 2 | 2 |
| Live attenuated bacterial vector | 0 | 2 |
| Viral vector (non-replicating) + antigen presenting cell | 1 | 0 |
| Bacterial vector (Replicating) | 0 | 1 |
| Cellular based vaccine | 0 | 1 |
| Total | 102 | 185 |
Source: WHO